Furthermore, low mRNA expression of NFAT1 led to a worse OS in patients with LUAD and LUSC, particularly for stage 1, indicating the tumor suppressor role of NFAT1 in NSCLC. This evidence concerns the gene NFATC2 and non-small cell lung carcinoma.